Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals Inc on Wednesday paused enrollment in a late-stage study testing its rare blood-disorder drug in adults with severe COVID-19 requiring mechanical ventilation.

Wall Street's main indexes opened higher on Monday as travel stocks surged on the launch of a nationwide COVID-19 vaccine campaign, while Alexion Pharmaceuticals jumped following a bumper buyout offer from Britain's AstraZeneca.

AstraZeneca shares fell as much as 9% on Monday, as investors moved to price in the costs of a $39 billion deal for U.S. biotech company Alexion Pharmaceuticals that would be the British drugmaker's biggest ever corporate acquisition.

The largest acquisition in AstraZeneca’s history is bold as well as big. The British drugmaker on Saturday announced it is buying U.S biotech Alexion Pharmaceuticals, which makes treatment for a rare immune disease, for $39 billion in cash and stock. Competitive challenges...

Shares of AstraZeneca fell 8% early on Monday, hit by doubts about the British firm's strategy and speculation of a rival bid after it announced the $39 billion purchase of Alexion Pharmaceuticals over the weekend.

Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs.

Astrazeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.

The U.S. Food and Drug Administration on Saturday approved Roche's Enspryng for the central nervous system disorder neuromyelitis optica, putting the Swiss drugmaker head-to-head with Alexion's Soliris in a costly treatment area.

Alexion Pharmaceuticals Inc will pay nearly $21.5 million to resolve claims it improperly paid Turkish and Russian officials to secure favorable treatment for its main drug, Soliris, the U.S. Securities and Exchange Commission said Thursday.

Alexion Pharmaceuticals <ALXN.O> has agreed to pay $21 million to resolve U.S. charges that it violated a major anti-corruption law when two of its subsidiaries paid Turkish and Russian officials for favorable treatment of its Soliris drug, the top securities regulator said...

* ALEXION PHARMACEUTICALS-ULTOMIRIS GETS MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS,CHILDREN WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME Source text for Eikon: Further company coverage:

* ALEXION ANNOUNCES PHASE 3 STUDY OF WEEKLY SUBCUTANEOUS ULTOMIRIS® (RAVULIZUMAB-CWVZ) MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Hedge fund Elliott Management on Tuesday publicly called on Alexion Pharmaceuticals Inc to sell itself, arguing that management's steps, including recent plans to acquire a smaller company, were leading in the wrong direction.

Activist investor Elliott Management on Tuesday revived its call for a sale of Alexion Pharmaceuticals Inc, months after the company rejected the hedge fund's earlier demand.

* ELLIOTT ADVISORS, IN LETTER TO ALEXION, SAYS BEST APPROACH FOR ALEXION IS IMMEDIATE EXPLORATION OF A SALE

* Q1 REVENUE $1.445 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.36 BILLION

* PORTOLA PHARMACEUTICALS CANCELS FIRST QUARTER 2020 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL FOLLOWING AGREEMENT TO BE ACQUIRED BY ALEXION Source text for Eikon: Further company coverage:

Alexion Pharmaceuticals Inc <ALXN.O> on Tuesday agreed to buy Portola Pharmaceuticals Inc <PTLA.O> in a $1.41 billion deal, as it looks to exploit smaller rival's blood-thinning antidote which has reached only a tiny portion of its target population.